The relevant disclosure is attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.3 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fortis Malar Hospitals reported Q1 FY26 (quarter ended June 30, 2025) results, with revenue from operations at zero following a slump sale of its hospital business. Standalone profit after tax stood at ₹417.65 lakhs versus a loss of ₹35.31 lakhs in Q1 FY25, largely driven by a one-time reversal of a minimum wages provision of ₹408.20 lakhs recorded as other income. The auditor flagged an emphasis-of-matter noting the company has ceased business operations with no visibility of restarting, while management is evaluating corporate restructuring options. The company holds cash and bank balances of around ₹3,232.39 lakhs and continues to be reported on a going-concern basis.
The stock is now effectively a cash shell with no operating business, making future returns dependent entirely on how the ~₹3,232 lakhs of cash is deployed or returned to shareholders through restructuring. Investors should note large unresolved tax disputes — VAT demands of ~₹25,455 lakhs, income tax appeals of ~₹150.61 lakhs, and GST appeal of ~₹4.82 lakhs — which pose meaningful downside risk if ruled against the company.